Oxogestone
(Redirected from 20β-hydroxy-19-norprogesterone)
 | |
| Clinical data | |
|---|---|
| Other names | Oxagestone; Oxagesterone; Oxogesterone; 20β-Hydroxy-19-norprogesterone; (20R)-20-Hydroxy-19-norpregn-4-en-3-one |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H30O2 |
| Molar mass | 302.458 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Oxogestone (INN), also known as 20β-hydroxy-19-norprogesterone, is a progestin of the 19-norprogesterone group which was synthesized in 1953 and was developed as an injectable hormonal contraceptive in the early 1970s but was never marketed.[1][2][3][4][5] A C20β phenylpropionate derivative, oxogestone phenpropionate, also exists.[1]
References
[edit]- ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 919–. ISBN 978-1-4757-2085-3.
- ^ Milne GW (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 1577–. ISBN 978-1-351-78989-9.
- ^ Farkas M, Szontágh FE (March 1972). "Clinical experiences concerning the intramuscular contraceptive oxogestone". Acta Europaea Fertilitatis. 3 (1): 37–43. PMID 4679651.
- ^ Ruíz Velasco V, Alisedo Aparicio LE (1972). "[Side effects of depot contraceptives]". La Prensa Medica Mexicana (in Spanish). 37 (1): 25–29. PMID 5032612.
- ^ Bassol S, Garza-Flores J (May 1994). "Review of ovulation return upon discontinuation of once-a-month injectable contraceptives". Contraception. 49 (5): 441–453. doi:10.1016/0010-7824(94)90003-5. PMID 8045131.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
 | This article about a steroid is a stub. You can help Wikipedia by expanding it. |